• # LGM Pharma is a Etoposide CAS# 33419-42-0 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Etoposide
  • CAS #: 33419-42-0
  • Mode of Action:

    Etoposide inhibits DNA topoisomerase II, thereby inhibiting DNA re-ligation. This causes critical errors in DNA synthesis at the premitotic stage of cell division and can lead to apoptosis of the cancer cell.. Etoposide is cell cycle dependent and phase specific, affecting mainly the S and G2 phases of cell division.

  • Pharmacodynamics:

    Etoposide is an antineoplastic agent and an epipodophyllotoxin (a semisynthetic derivative of the podophyllotoxins). It inhibits DNA topoisomerase II, thereby ultimately inhibiting DNA synthesis. Etoposide is cell cycle dependent and phase specific, affecting mainly the S and G2 phases. Two different dose-dependent responses are seen. At high concentrations (10 µg/mL or more), lysis of cells entering mitosis is observed. At low concentrations (0.3 to 10 µg/mL), cells are inhibited from entering prophase. It does not interfere with microtubular assembly. The predominant macromolecular effect of etoposide appears to be the induction of DNA strand breaks by an interaction with DNA-topoisomerase II or the formation of free radicals.

  • Metabolism:

    Primarily hepatic (through O-demethylation via the CYP450 3A4 isoenzyme pathway) with 40% excreted unchanged in the urine.

  • Toxicity:

    Side effects include alopecia, constipation, diarrhea, nausea and vomiting and secondary malignancies (leukemia).

  • IUPAC: (10R, 11R, 15R, 16S)-16-{[(2R, 4aR, 6R, 7R, 8R, 8aS)-7, 8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3, 2-d][1, 3]dioxin-6-yl]oxy}-10-(4-hydroxy-3, 5-dimethoxyphenyl)-4, 6, 13-trioxatetracyclo[7.7.0.0, {3, 7}.0, {11, 15}]hexadeca-1(9), 2, 7-trien-12-one
  • ATC: L01CB01
  • PubChem: 36462
  • DrugBank: DB00773 (APRD00239)
  • Formula: C22H28N2O
  • Molecular Mass: 588.5566
  • Synonyms: (-)-Etoposide Etoposidum [INN-Latin] trans-Etoposide
  • SMILES: COC1=CC(=CC(OC)=C1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)C2=CC3=C(OCO3)C=C12
  • AHFS Code: 10:00.0
  • InChl: VJJPUSNTGOMMGY-MRVIYFEKSA-N
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service